At least five hedge funds have benefited from two biopharma stocks that went public in February and are currently doing well.
Stephen TaubFebruary 27, 2023
Nicky Loh/Bloomberg
A pair of IPOs this month is generating some cautious optimism that the new-issues market may have finally emerged from its bear market slumber. Both Mineralys Therapeutics and Structure Therapeutics are currently trading above their offering
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.